7-2538147-T-C

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_152743.4(BRAT1):​c.2388A>G​(p.Glu796Glu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.363 in 1,607,532 control chromosomes in the GnomAD database, including 111,247 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.45 ( 17030 hom., cov: 34)
Exomes 𝑓: 0.35 ( 94217 hom. )

Consequence

BRAT1
NM_152743.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: -0.444

Publications

18 publications found
Variant links:
Genes affected
BRAT1 (HGNC:21701): (BRCA1 associated ATM activator 1) The protein encoded by this ubiquitously expressed gene interacts with the tumor suppressing BRCA1 (breast cancer 1) protein and and the ATM (ataxia telangiectasia mutated) protein. ATM is thought to be a master controller of cell cycle checkpoint signalling pathways that are required for cellular responses to DNA damage such as double-strand breaks that are induced by ionizing radiation and complexes with BRCA1 in the multi-protein complex BASC (BRAC1-associated genome surveillance complex). The protein encoded by this gene is thought to play a role in the DNA damage pathway regulated by BRCA1 and ATM. [provided by RefSeq, Mar 2012]
BRAT1 Gene-Disease associations (from GenCC):
  • neonatal-onset encephalopathy with rigidity and seizures
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Orphanet, ClinGen, G2P, Labcorp Genetics (formerly Invitae)
  • neurodevelopmental disorder with cerebellar atrophy and with or without seizures
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen, Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.77).
BP6
Variant 7-2538147-T-C is Benign according to our data. Variant chr7-2538147-T-C is described in ClinVar as Benign. ClinVar VariationId is 585490.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.444 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.664 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
BRAT1NM_152743.4 linkc.2388A>G p.Glu796Glu synonymous_variant Exon 14 of 14 ENST00000340611.9 NP_689956.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
BRAT1ENST00000340611.9 linkc.2388A>G p.Glu796Glu synonymous_variant Exon 14 of 14 1 NM_152743.4 ENSP00000339637.4
BRAT1ENST00000467558.5 linkn.4174A>G non_coding_transcript_exon_variant Exon 10 of 10 5
BRAT1ENST00000469750.5 linkn.4960A>G non_coding_transcript_exon_variant Exon 11 of 11 2
BRAT1ENST00000493232.5 linkn.5094A>G non_coding_transcript_exon_variant Exon 3 of 3 2

Frequencies

GnomAD3 genomes
AF:
0.449
AC:
68279
AN:
152070
Hom.:
16997
Cov.:
34
show subpopulations
Gnomad AFR
AF:
0.670
Gnomad AMI
AF:
0.462
Gnomad AMR
AF:
0.420
Gnomad ASJ
AF:
0.286
Gnomad EAS
AF:
0.366
Gnomad SAS
AF:
0.338
Gnomad FIN
AF:
0.489
Gnomad MID
AF:
0.329
Gnomad NFE
AF:
0.338
Gnomad OTH
AF:
0.423
GnomAD2 exomes
AF:
0.387
AC:
93845
AN:
242584
AF XY:
0.377
show subpopulations
Gnomad AFR exome
AF:
0.675
Gnomad AMR exome
AF:
0.428
Gnomad ASJ exome
AF:
0.297
Gnomad EAS exome
AF:
0.359
Gnomad FIN exome
AF:
0.483
Gnomad NFE exome
AF:
0.345
Gnomad OTH exome
AF:
0.371
GnomAD4 exome
AF:
0.354
AC:
514874
AN:
1455344
Hom.:
94217
Cov.:
54
AF XY:
0.351
AC XY:
254034
AN XY:
722856
show subpopulations
African (AFR)
AF:
0.680
AC:
22692
AN:
33392
American (AMR)
AF:
0.429
AC:
19116
AN:
44562
Ashkenazi Jewish (ASJ)
AF:
0.297
AC:
7752
AN:
26082
East Asian (EAS)
AF:
0.364
AC:
14380
AN:
39530
South Asian (SAS)
AF:
0.331
AC:
28462
AN:
86074
European-Finnish (FIN)
AF:
0.476
AC:
24619
AN:
51714
Middle Eastern (MID)
AF:
0.361
AC:
2074
AN:
5746
European-Non Finnish (NFE)
AF:
0.337
AC:
373846
AN:
1108188
Other (OTH)
AF:
0.365
AC:
21933
AN:
60056
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.484
Heterozygous variant carriers
0
21745
43489
65234
86978
108723
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
12226
24452
36678
48904
61130
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.449
AC:
68366
AN:
152188
Hom.:
17030
Cov.:
34
AF XY:
0.451
AC XY:
33547
AN XY:
74404
show subpopulations
African (AFR)
AF:
0.670
AC:
27844
AN:
41534
American (AMR)
AF:
0.421
AC:
6435
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
0.286
AC:
994
AN:
3472
East Asian (EAS)
AF:
0.365
AC:
1885
AN:
5164
South Asian (SAS)
AF:
0.336
AC:
1623
AN:
4824
European-Finnish (FIN)
AF:
0.489
AC:
5186
AN:
10596
Middle Eastern (MID)
AF:
0.340
AC:
100
AN:
294
European-Non Finnish (NFE)
AF:
0.338
AC:
22987
AN:
67978
Other (OTH)
AF:
0.422
AC:
891
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1825
3651
5476
7302
9127
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
612
1224
1836
2448
3060
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.387
Hom.:
5904
Bravo
AF:
0.455
Asia WGS
AF:
0.353
AC:
1227
AN:
3478
EpiCase
AF:
0.337
EpiControl
AF:
0.338

ClinVar

Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3
Jul 15, 2024
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 60% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 56. Only high quality variants are reported.

Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

not provided Benign:2
Jul 07, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Apr 20, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Neonatal-onset encephalopathy with rigidity and seizures Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.77
CADD
Benign
1.5
DANN
Benign
0.43
PhyloP100
-0.44
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1043291; hg19: chr7-2577781; COSMIC: COSV61394529; COSMIC: COSV61394529; API